Journal of Biological Chemistry · 2006 · 130 citations · 43 references
Life SciencesNeurosciencePharmacologyMolecular NeuroscienceNeurochemistryNeuropharmacologyCholinergic PharmacologyCholinergic SignalingNeurotransmissionNeurotransmitter ReceptorsReceptor PhysiologySynaptic TransmissionCholinergic Receptor PharmacologyDisulfide Bond AnalysisDisulfide Bond ConnectivityDisulfide Bond StabilityDisulfide Bond StructureDisulfide LinkersNeuropathic Pain ModulationNicotinic Receptor Pharmacology
The α-conotoxin Vc1.1 is a small disulfide-bonded peptide currently in development as a treatment for neuropathic pain. This study describes the synthesis, determination of the disulfide connectivity, and the determination of the three-dimensional structure of Vc1.1 using NMR spectroscopy. Vc1.1 was shown to inhibit nicotine-evoked membrane currents in isolated bovine chromaffin cells in a concentration-dependent manner and preferentially targets peripheral nicotinic acetylcholine receptor (nAChR) subtypes over central subtypes. Specifically, Vc1.1 is selective for α3-containing nAChR subtypes. The three-dimensional structure of Vc1.1 comprises a small α-helix spanning residues Pro6 to Asp11 and is braced by the I-III, II-IV disulfide connectivity seen in other α-conotoxins. A comparison of the structure of Vc1.1 with other α-conotoxins, taken together with nAChR selectivity data, suggests that the conserved proline at position 6 is important for binding, whereas a number of residues in the C-terminal portion of the peptide contribute toward the selectivity. The structure reported here should open new opportunities for further development of Vc1.1 or analogues as analgesic agents. The α-conotoxin Vc1.1 is a small disulfide-bonded peptide currently in development as a treatment for neuropathic pain. This study describes the synthesis, determination of the disulfide connectivity, and the determination of the three-dimensional structure of Vc1.1 using NMR spectroscopy. Vc1.1 was shown to inhibit nicotine-evoked membrane currents in isolated bovine chromaffin cells in a concentration-dependent manner and preferentially targets peripheral nicotinic acetylcholine receptor (nAChR) subtypes over central subtypes. Specifically, Vc1.1 is selective for α3-containing nAChR subtypes. The three-dimensional structure of Vc1.1 comprises a small α-helix spanning residues Pro6 to Asp11 and is braced by the I-III, II-IV disulfide connectivity seen in other α-conotoxins. A comparison of the structure of Vc1.1 with other α-conotoxins, taken together with nAChR selectivity data, suggests that the conserved proline at position 6 is important for binding, whereas a number of residues in the C-terminal portion of the peptide contribute toward the selectivity. The structure reported here should open new opportunities for further development of Vc1.1 or analogues as analgesic agents. Conotoxins are peptide toxins, ranging in size from 12 to 30 amino acids, isolated from the venom of snails from the Conus genus (1Terlau H. Olivera B.M. Physiol. Rev. 2004; 84: 41-68Crossref PubMed Scopus (790) Google Scholar). Members of this peptide family target a range of membrane receptors with both high potency and selectivity and as a consequence are useful as neuropharmacological probes and have a range of potential pharmaceutical applications. The α-conotoxins are a subfamily of conotoxins that typically range in size from 12 to 16 amino acids, which contain two disulfide bonds in a I-III, II-IV connectivity and have an amidated C terminus. The α-conotoxins interact with both muscle and neuronal nicotinic acetylcholine receptors (nAChRs), 3The abbreviations used are: nAChR, nicotinic acetylcholine receptor; ACh, acetylcholine; DQF-COSY, double quantum filtered correlated spectroscopy; RP-HPLC, reversed-phase-high performance liquid chromatography; IC50, half-maximal inhibitory concentration; MS, mass spectrometry; MS/MS, tandem mass spectrometry; ES-MS, electrospray-mass spectrometry; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser effect spectroscopy; TOCSY, total correlation spectroscopy; MES, 2-morpholinoethanesulfonic acid; r.m.s.d., root mean square deviation.3The abbreviations used are: nAChR, nicotinic acetylcholine receptor; ACh, acetylcholine; DQF-COSY, double quantum filtered correlated spectroscopy; RP-HPLC, reversed-phase-high performance liquid chromatography; IC50, half-maximal inhibitory concentration; MS, mass spectrometry; MS/MS, tandem mass spectrometry; ES-MS, electrospray-mass spectrometry; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser effect spectroscopy; TOCSY, total correlation spectroscopy; MES, 2-morpholinoethanesulfonic acid; r.m.s.d., root mean square deviation. which have been implicated in a range of disorders, including Alzheimer disease, schizophrenia, depression, and small cell lung carcinoma, and they play a role in analgesia and addiction (2McIntosh J.M. Santos A.D. Olivera B.M. Annu. Rev. Biochem. 1999; 68: 59-88Crossref PubMed Scopus (275) Google Scholar, 3Adams D.J. Alewood P.F. Craik D.J. Drinkwater R.D. Lewis R.J. Drug Dev. Res. 1999; 46: 219-234Crossref Scopus (109) Google Scholar, 4Dutton J.L. Craik D.J. Curr. Med. Chem. 2001; 8: 327-344Crossref PubMed Scopus (96) Google Scholar, 5Livett B.G. Gayler K.R. Khalil Z. Curr. Med. Chem. 2004; 11: 1715-1723Crossref PubMed Scopus (138) Google Scholar). Selected α-conotoxin examples are shown below in Fig. 1. The α-conotoxin Vc1.1 was first discovered using a PCR screen of cDNAs from the venom ducts of Conus victoriae (6Sandall D.W. Satkunanathan N. Keays D.A. Polidano M.A. Liping X. Pham V. Down J.G. Khalil Z. Livett B.G. Gayler K.R. Biochemistry. 2003; 42: 6904-6911Crossref PubMed Scopus (168) Google Scholar). The cysteine spacing within the sequence of Vc1.1 suggests that it is a member of the 4/7 subclass of α-conotoxins, which includes the extensively studied conotoxins MII, EpI and PnIB, although the actual disulfide connectivity of Vc1.1 has yet to be reported. In addition to an amidated C terminus, which is common to all α-conotoxins, Pro6 and Glu14 in Vc1.1 are post-translationally modified to hydroxyproline and γ-carboxyglutamate, respectively. The post-translationally modified peptide, designated vc1a, was recently identified in the venom of C. victoriae using MS analysis (7Jakubowski J.A. Keays D.A. Kelley W.P. Sandall D.W. Bingham J.P. Livett B.G. Gayler K.R. Sweedler J.V. J. Mass Spectrom. 2004; 39: 548-557Crossref PubMed Scopus (53) Google Scholar). Synthetic Vc1.1, an antagonist of neuronal nAChRs in bovine chromaffin cells, has been shown to alleviate neuropathic pain in three rat models of human neuropathic pain and to accelerate the functional recovery of injured neurons (8Satkunanathan N. Livett B. Gayler K. Sandall D. Down J. Khalil Z. Brain Res. 2005; 1059: 149-158Crossref PubMed Scopus (155) Google Scholar). As an analgesic, Vc1.1 has been reported be more active than ω-conotoxin MVIIA, a conotoxin that has recently been approved as a treatment for intractable pain (6Sandall D.W. Satkunanathan N. Keays D.A. Polidano M.A. Liping X. Pham V. Down J.G. Khalil Z. Livett B.G. Gayler K.R. Biochemistry. 2003; 42: 6904-6911Crossref PubMed Scopus (168) Google Scholar). More recently, Vc1.1 was shown to antagonize the nicotine-induced increase in axonal excitability of unmyelinated C-fiber axons in isolated segments of peripheral human nerves (9Lang P.M. Burgstahler R. Haberberger R.V. Sippel W. Grafe P. Neuroreport. 2005; 16: 479-483Crossref PubMed Scopus (27) Google Scholar). Electrophysiological and immunohistochemical data indicate the functional expression of nAChRs composed of α3, α5, and β4 but not α4, β2, or α7 subunits in axons of unmyelinated C fibers (9Lang P.M. Burgstahler R. Haberberger R.V. Sippel W. Grafe P. Neuroreport. 2005; 16: 479-483Crossref PubMed Scopus (27) Google Scholar, 10Lang P.M. Burgstahler R. Sippel W. Irnich D. Schlotter-Weigel B. Grafe P. J. Neurophysiol. 2003; 90: 3295-3303Crossref PubMed Scopus (61) Google Scholar). Blockade of nAChRs on unmyelinated peripheral nerve fibers may have an analgesic effect on unmyelinated sympathetic and/or sensory axons. Interestingly, synthetic vc1a was reported to not inhibit the neuronal-type nicotinic response in chromaffin cells and was inactive in two rat neuropathic pain assays (7Jakubowski J.A. Keays D.A. Kelley W.P. Sandall D.W. Bingham J.P. Livett B.G. Gayler K.R. Sweedler J.V. J. Mass Spectrom. 2004; 39: 548-557Crossref PubMed Scopus (53) Google Scholar). Vc1.1 is now under development as a treatment for neuropathic pain (5Livett B.G. Gayler K.R. Khalil Z. Curr. Med. Chem. 2004; 11: 1715-1723Crossref PubMed Scopus (138) Google Scholar, 11Gayler K. Sandall D. Greening D. Keays D. Polidano M. Livett B. Down J. Satkunanathan N. Khalil Z. IEEE Eng. Med. Biol. Mag. 2005; 24: 79-84Crossref PubMed Scopus (14) Google Scholar) but neither a specific receptor target nor the structure has been reported. Herein, we report the three-dimensional structure of Vc1.1 in solution as determined by NMR spectroscopy and explicitly determine the disulfide connectivity via chemical reduction and MS analysis. In addition, we show that Vc1.1 selectively antagonizes peripherally expressed nAChRs subtypes over those typically expressed in the central nervous system. These findings provide an insight into the potential modes of action of this analgesic peptide. We also examined the structure and activity of two derivatives of Vc1.1, vc1a and [P6O]-Vc1.1, which contain the post-translationally modified residues hydroxyproline and γ-carboxyglutamic and to findings for and vc1a, and on by peptide using the in for M. Alewood P. Alewood D. J. Res. PubMed Scopus Google Scholar). of the peptide from the was using with and as The was to at to for The was under and the peptide was with in and The by on a using a of acid; in and the was at These used in and the and mass of the The by in at a of and at The by RP-HPLC, and the was by of was in of and of in was The was at for the The peptide was and an of in was The was at for and the was isolated by and The peptide was in and with an of in a peptide with two and two This peptide was by to the of the in the NMR data for Vc1.1, vc1a, and on in at and used in the of NMR DQF-COSY, TOCSY, and NOESY, with all at K. A of and of Vc1.1 in used in the determination of on using and to at on for Vc1.1 was from a with a of at K. used to determine determined from from analysis of the in a high or from a The was to for for and used in of also 12 for 6 bonds identified from data and using P. C. K. J. Biol. PubMed Scopus Google and the structure using a with PubMed Scopus Google Scholar). This a high of of a with of of which the is to and an of The to further and in a J.P. M. J. 1999; PubMed Scopus Google Scholar). The in the to via of of of of of at a the is in of of of the with of and the with the for analysis. using the R. M. K. J. Scopus Google Scholar) and with J.M. PubMed Scopus Google Scholar) and J.A. R. J.M. J. 8: PubMed Scopus Google Scholar). Electrophysiological from nAChRs in and in cells from bovine and on in as J. Biochem. PubMed Scopus Google Scholar). and of with solution in solution and to cells by from an from the cell to to H. D.J. J. 2005; PubMed Scopus Google Scholar). Conotoxins and with the in the currents by and filtered using an and from a using and a at and expression of nAChR subunits in as Alewood P.F. D.J. D. J. Biol. Chem. 2003; PubMed Scopus Google Scholar). with the rat and nAChR subunits by J. of and into the expression with of the and nAChRs in which of was to expression and at in at with and currents from using an with in including and analysis the and from and of with at using a solution of as was by as the in the solution for at the at a of with for the was for at with applications. at a potential of at and filtered at was and of the data for by to the is the is the antagonist is the is the and is the of antagonist that of the was using The of and recovery from from to the data using The for the was using and The of by of the J. PubMed Scopus Google is the of the of the is the of the by is the of the and is the The to the data the at a to which in the of to J. PubMed Scopus Google Scholar). and sequence of Vc1.1 is shown in Fig. 1. The post-translationally modified of Vc1.1, vc1a, which is in the a hydroxyproline in position 6 and a γ-carboxyglutamic in position further the of modified residues a peptide, [P6O]-Vc1.1, was that a hydroxyproline in position 6 but the at position Vc1.1, vc1a, and using on The of on the was The of the in are shown in Fig. three Vc1.1, vc1a, and a with a of and determined by of vc1a, and by with in at The was by RP-HPLC, and the was with The peptide was and by all three the data that and been with from both of the peptide and the it was that the disulfide connectivity of Vc1.1, vc1a, and was to and to This is with the I-III, II-IV disulfide seen in other α-conotoxins. NMR and from the used in the of the determined from the in all three for the peptide at Pro6 and in the of proline residues and that the bonds in the of chemical data that residues and all have a This is further by the small for Vc1.1 and the of the for of residues This of is of other α-conotoxin reported to J.L. Craik D.J. Curr. Med. Chem. 2001; 8: 327-344Crossref PubMed Scopus (96) Google Scholar). Fig. and the high of the three The are for is a in at 6 and/or This in structure is by the the for vc1a at position 6 both a hydroxyproline at this and Vc1.1 at position A comparison of the chemical the shown in Fig. suggests that the in are also in activity the three is to in the of the than of solution structure of Vc1.1 was determined by using on and on The and which and range and the as of the solution structure of Vc1.1 as shown in Fig. A of the and for the family of is in 1. The are in with the data, and and for the family of the solution of in a new In the of Vc1.1, shown in Fig. is with that seen in other α-conotoxins. The is an α-helix spanning residues Pro6 to In addition, J.M. PubMed Scopus Google Scholar) a at the of the peptide for residues to of the in the the disulfide of Vc1.1 is as a and in the of the is not by In all the disulfide is in a A comparison of the disulfide in Vc1.1 with the of and in with the P. R. D. V. Biol. 2005; PubMed Scopus Google Scholar) that the disulfide of both is to that of the disulfide of Vc1.1 and of Vc1.1 at functional activity of Vc1.1 was via on nicotine-evoked membrane currents in bovine chromaffin of Vc1.1 membrane currents in chromaffin cells at of the the nicotine-evoked in chromaffin cells, which Fig. the for of nicotine-evoked by The to a half-maximal inhibitory of and of The of of of nicotine-evoked in the of and the recovery from by and of nAChR and of potency and of Vc1.1 of and a to of from to of was and was with a using a of was Fig. cell membrane currents by of to the chromaffin cell at membrane cell for nicotine-evoked currents in the and of and Vc1.1 are shown in Fig. Vc1.1 nicotine-evoked by and at all membrane in the of and Vc1.1, that the of nAChRs by Vc1.1 was of nAChRs in chromaffin cells by Vc1.1 was from determined in the and of of A of the was for nicotine-induced currents in the of and Vc1.1 from of in the and of Vc1.1 of The of the not from the of the of the at the of Vc1.1 of nAChR of currents was examined in nAChRs The response was and the was to of the Vc1.1 to inhibit currents by the central nAChR and or the muscle nAChR and Vc1.1 of the by the neuronal nAChR, α7 and Vc1.1 the peripheral nAChR subtypes and to a and of respectively. A potency was addition of the to the nAChR but Vc1.1 potency to inhibit of Vc1.1 at of not antagonize currents nor a response for α3-containing In a of to and with at and has been shown to inhibit neuronal nAChRs J. M. 2004; PubMed Scopus Google Scholar, D.J. J. Physiol. PubMed Scopus Google at Vc1.1 which was more than that at not Vc1.1 of nAChR expressed in was from to the data at of 30 and was from to the data at of 30 in a new The post-translationally modified vc1a and also examined in under the as of vc1a or to inhibit currents by and nAChRs expressed in of vc1a and also inactive on the and subtypes not In this study we have the α-conotoxin Vc1.1, determined disulfide connectivity and three-dimensional and identified selectivity and potency for nAChR subtypes. The peptide was to into which was determined to have a I-III, II-IV disulfide connectivity common to all α-conotoxins. These two disulfide bonds are the for the of the and provide Vc1.1 was shown to inhibit the nicotine-induced membrane in bovine chromaffin cells in a concentration-dependent manner with a potency with the of of (6Sandall D.W. Satkunanathan N. Keays D.A. Polidano M.A. Liping X. Pham V. Down J.G. Khalil Z. Livett B.G. Gayler K.R. Biochemistry. 2003; 42: 6904-6911Crossref PubMed Scopus (168) Google Scholar). Vc1.1 selectivity for α3-containing with potency for and nAChR The potency of was not by the addition of the whereas the addition of the to the potency In Vc1.1 of from chromaffin cell of and which suggests that Vc1.1 is a specific of of the nAChR subtypes (6Sandall D.W. Satkunanathan N. Keays D.A. Polidano M.A. Liping X. Pham V. Down J.G. Khalil Z. Livett B.G. Gayler K.R. Biochemistry. 2003; 42: 6904-6911Crossref PubMed Scopus (168) Google Scholar). Vc1.1 preferentially targets peripheral over central nAChR but the the and assays The modified analogues vc1a and not inhibit currents by of the nAChR subtypes expressed in The of activity of vc1a on neuronal nAChR subtypes is with that reported in bovine chromaffin cells and rat models of neuropathic pain B. Khalil Z. Gayler K. Down J. conotoxin with analgesic Scholar). The three-dimensional structure of Vc1.1 that it is a by a over residues Pro6 to The for the in the family of is which that the structure of the is the three-dimensional of Vc1.1 is to those for other 4/7 α-conotoxins. a comparison of Vc1.1 with EpI M. R. Alewood P.F. Lewis R.J. J.L. Biochemistry. PubMed Scopus (53) Google J.M. Bingham J.P. Alewood P.F. Craik D.J. Biochemistry. PubMed Scopus Google Scholar, Olivera B.M. J.M. Biochemistry. PubMed Scopus Google and J. Alewood P.F. Craik D.J. J.L. Biochemistry. PubMed Scopus Google Scholar) that the with of and respectively. A comparison of the NMR chemical data for vc1a and with that for Vc1.1 that two post-translationally modified analogues to Vc1.1, the of activity of two was to the and not a the of Vc1.1, shown in Fig. from other 4/7 α-conotoxins. This of conotoxins typically has a of residues on that is to play a role in receptor and is from Fig. that Vc1.1 has residues on than the α-conotoxins EpI and which are selective for the and nAChR respectively. Vc1.1 a number of common from the conserved with other α-conotoxins. The proline in position 6 is in all α-conotoxins for the recently discovered which at a on the nAChR M. J.M. Olivera B.M. J. Biol. Chem. 2003; PubMed Scopus Google Scholar). This proline has both a role and is also to contribute a with the of the nAChR Lewis R.J. J. Biol. Chem. 2005; PubMed Scopus (61) Google Scholar). three of α-conotoxins in with the have been P. R. D. V. Biol. 2005; PubMed Scopus Google Scholar, P. P. J. 2005; 24: PubMed Scopus Google Scholar, C. D. V. PubMed Scopus Google Scholar). three that α-conotoxins, which includes is a to receptor In the post-translationally modified of Vc1.1, vc1a, Pro6 is to a hydroxyproline and Glu14 is to a γ-carboxyglutamic (7Jakubowski J.A. Keays D.A. Kelley W.P. Sandall D.W. Bingham J.P. Livett B.G. Gayler K.R. Sweedler J.V. J. Mass Spectrom. 2004; 39: 548-557Crossref PubMed Scopus (53) Google Scholar). This modified peptide not inhibit the nicotine-induced response in chromaffin cells (7Jakubowski J.A. Keays D.A. Kelley W.P. Sandall D.W. Bingham J.P. Livett B.G. Gayler K.R. Sweedler J.V. J. Mass Spectrom. 2004; 39: 548-557Crossref PubMed Scopus (53) Google and we show here that this is to a of activity at the and nAChR subtypes. or both of in the of activity seen for vc1a, and it that the hydroxyproline is the of this the conserved with the The role of was by of [P6O]-Vc1.1, which has a hydroxyproline at position 6 but the at position This peptide was also inactive on the nAChR and the role of Pro6 in the of the conotoxin with the the of the the Fig. the structure of Vc1.1 over the of The structure is from the structure of a 4/7 to the from P. R. D. V. Biol. 2005; PubMed Scopus Google Scholar). The is a of the of the As be seen in Fig. the conserved Pro6 has with both and whereas Glu14 is and to be important for the of the conotoxin to the receptor but may the selectivity of This is also with a study on PnIB, which that the proline at position 6 with a hydroxyproline in a reduction in activity of at the α7 nAChR J.M. J. Biol. Chem. PubMed Scopus Google Scholar). In α-conotoxins it is that the selectivity for and over the α7 nAChR expressed in is by the of the of the at position with to α7 selectivity J.M. J. Biol. Chem. PubMed Scopus Google Scholar, Olivera B.M. D. J.M. Biochemistry. 1999; PubMed Scopus Google Scholar, N. J. Down J. Alewood P. Livett B. J. PubMed Scopus Google Scholar, M. Lewis R.J. 2003; PubMed Scopus Google Scholar). Vc1.1 has a to or in other α-conotoxins, at position and is selective for the over the α7 nAChR The structure of Vc1.1 here that the of this is and the of this and the may of Vc1.1 with the α7 nAChR Vc1.1 has an sequence to EpI for the first but in of the C-terminal The sequence is in the of the two shown in Fig. The of the portion of Vc1.1 and EpI a of and EpI is a of nAChRs in both bovine chromaffin cells and rat neurons that are in and M. J. D.J. Livett B.G. Down J.G. Alewood P.F. Lewis R.J. J. Biol. Chem. PubMed Scopus Google Scholar). EpI rat α7 nAChR subtypes expressed in and has effect on and subtypes M. Lewis R.J. 2003; PubMed Scopus Google Scholar). Vc1.1 activity at the α7 nAChR subtypes expressed in it is active in nicotine-induced membrane currents and from bovine chromaffin cells and is active on and nAChR subtypes expressed in This suggests that the in activity for EpI and Vc1.1 at the rat α7 nAChR expressed in be residues to be the of this a in position has been shown in to with the α7 J.M. J. Biol. Chem. PubMed Scopus Google Scholar). In addition, of to in activity at the α7 nAChR by Vc1.1 has an in position than the in and this may also contribute to the of activity of Vc1.1 on the α7 the α-conotoxin has been shown to be a of the nAChR it was to be selective for the α7 receptor C. D. V. PubMed Scopus Google Scholar, M. J.M. Olivera B.M. Biochemistry. 2004; PubMed Scopus Google Scholar). is in sequence to Vc1.1 from residues and the activity of on receptors is with the activity of Vc1.1 and the in the of and Vc1.1 the is active on the α7 nAChR and Vc1.1 is has a and it has been shown that is important for activity J. Biol. Chem. PubMed Scopus Google Scholar). of with in a in whereas with activity that an is at position of residues and in effect on activity at the α7 J. Biol. Chem. PubMed Scopus Google Scholar). The structure of to that a number of with the of the receptor at that the 4/7 α-conotoxin not C. D. V. PubMed Scopus Google Scholar). Vc1.1 has a in position which has an yet also a may be this that is with the with the α7 or it may be a of the a of the The of the 4/7 α-conotoxin have been studied in recently D. J.M. Biochemistry. 2004; PubMed Scopus Google Scholar, J.M. C. J.M. P. 2004; PubMed Scopus Google Scholar). Interestingly, both and Vc1.1 on nAChR but are in activity is in the has a selectivity for than Vc1.1, but has a potency for subtypes. also has a potency for the α7 nAChR whereas Vc1.1 has effect D. Olivera B.M. J.M. J. Biol. Chem. PubMed Scopus Google Scholar, J. C. J. 39: PubMed Scopus Google Scholar). of that the and a effect on potency at the and nAChR whereas and more for subtypes D. J.M. Biochemistry. 2004; PubMed Scopus Google Scholar, J.M. C. J.M. P. 2004; PubMed Scopus Google Scholar). of and to has been shown to increase the selectivity of for nAChRs J.M. C. J.M. P. 2004; PubMed Scopus Google Scholar). In addition to the conserved proline at position of the residues important for the activity of are in the sequence of have a at position in Vc1.1 and in MII, that may contribute to the selectivity of and Vc1.1 for the and Vc1.1 also both have a at position and as the potency of was to be it has been that this is in the active of the peptide D. J.M. Biochemistry. 2004; PubMed Scopus Google Scholar). We have that a reduction of the potency of Vc1.1, which the that a may be important for the receptor the at position in is with in Vc1.1, which have a with the the structure and activity data that it is the portion of Vc1.1 that is the of to the nAChR, with residues in the C-terminal portion of the for more on potency and selectivity. this is the first report on the selectivity of Vc1.1 for nAChR subtypes. Vc1.1 been on the reported chromaffin cell to be selective for subtypes (6Sandall D.W. Satkunanathan N. Keays D.A. Polidano M.A. Liping X. Pham V. Down J.G. Khalil Z. Livett B.G. Gayler K.R. Biochemistry. 2003; 42: 6904-6911Crossref PubMed Scopus (168) Google and the of the with nAChRs been We show that the potency of Vc1.1 was at but a reduction at nAChRs to The α7 nAChR in the of 30 We have that the post-translationally modified of Vc1.1, vc1a, which is in the not inhibit currents by of the nAChR subtypes expressed in This is an from a it that the is into it more that vc1a is to target an as yet receptor Vc1.1 has been reported to have an important to the potential role of nAChRs in pain (8Satkunanathan N. Livett B. Gayler K. Sandall D. Down J. Khalil Z. Brain Res. 2005; 1059: 149-158Crossref PubMed Scopus (155) Google it is to inhibit a response to pain (6Sandall D.W. Satkunanathan N. Keays D.A. Polidano M.A. Liping X. Pham V. Down J.G. Khalil Z. Livett B.G. Gayler K.R. Biochemistry. 2003; 42: 6904-6911Crossref PubMed Scopus (168) Google Scholar) and is to pain in models of human (8Satkunanathan N. Livett B. Gayler K. Sandall D. Down J. Khalil Z. Brain Res. 2005; 1059: 149-158Crossref PubMed Scopus (155) Google Scholar, P.M. Burgstahler R. Haberberger R.V. Sippel W. Grafe P. Neuroreport. 2005; 16: 479-483Crossref PubMed Scopus (27) Google Scholar). of nAChRs as Vc1.1 the increase in axonal excitability by neuronal nAChR (9Lang P.M. Burgstahler R. Haberberger R.V. Sippel W. Grafe P. Neuroreport. 2005; 16: 479-483Crossref PubMed Scopus (27) Google Scholar). The structure reported here should open new opportunities for further development of Vc1.1 or analogues as analgesic agents. We Livett and for of the
43